#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Retinopathy of prematurity Postprandial hypoglycaemia Small for dates baby Candida infection Crigler-Najjar syndrome Hypertriglyceridaemia Arteriovenous malformation Neuronal ceroid lipofuscinosis Myasthenia gravis Colitis ulcerative Uterine leiomyosarcoma Systemic mastocytosis Mantle cell lymphoma recurrent Testicular leiomyosarcoma Non-Hodgkin's lymphoma unspecified histology aggressive recurrent More trials…

    Learn about Rare Diseases

    Systemic mastocytosis – Trials in Disease Shprintzen-Goldberg syndrome – Diagnostics Carcinoid syndrome – Diagnostics Glycogen storage disease type V – Diagnostics Osteosarcoma recurrent – Treatment Myelodysplastic syndrome – Trials in Disease Skin angiosarcoma – Trials in Disease Haemolytic uraemic syndrome – Treatment Alexander disease – Trials in Disease Systemic sclerosis pulmonary More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    VERCIRNON Evencaleucel NORGESTIMATE Teprotumumab Prednisolone Acetate Ganciclovir Sodium Topotecan ABIRATERONE DECANOATE Taletrectinib Dalteparin Sodium Lomustine Pivmecillinam Hydrochloride Abt-494 Istem-01 Cldn6 Rna-Lpx Ttf-Ngr Tolebrutinib Enomimeran Masofaniten Fluorouracil Sodium More therapies…

    Learn about Your Condition

    Lymphangioleiomyomatosis Neurodegenerative disorder Aplastic anaemia Double hit lymphoma EGFR gene mutation Chondrosarcoma Phaeochromocytoma Osteonecrosis of jaw Gout Spondylolisthesis Radiation skin injury Erythema migrans Carpal tunnel syndrome Epilepsy Biliary tract operation More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hemic and Lymphatic Diseases

  • A study on the long-term safety and effectiveness of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B

    Recruiting

    3 1 1
    Investigated Drugs:
    • Fidanacogene Elaparvovec
    • Giroctocogene Fitelparvovec
    France Germany Greece Italy Spain Sweden

  • A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Elritercept
    • Epoetin Alfa
    Belgium Bulgaria France Germany Greece Hungary +8

  • Optimizing fludarabine phosphate exposure to improve event‑free survival in children and young adults with B‑cell acute lymphoblastic leukemia receiving CAR‑T therapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Fludarabine Phosphate
    Germany The Netherlands Spain

  • Glofitamab plus drug combination for relapsed/refractory large B‑cell lymphoma in high‑risk second‑line patients eligible for CAR‑T therapy

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Glofitamab
    • Axicabtagene Ciloleucel
    • Lisocabtagene Maraleucel
    Germany

  • Study of glofitamab, obinutuzumab and tocilizumab in patients with mantle cell lymphoma relapsed or refractory after CAR‑T therapy

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Glofitamab
    • Obinutuzumab
    • Tocilizumab
    Italy

  • Study of fludarabine phosphate in patients with blood cancer undergoing lymphodepletion before CAR-T cell therapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Haematological malignancy
    Investigated Drugs:
    • Brexucabtagene Autoleucel
    • Ciltacabtagene Autoleucel
    • Axicabtagene Ciloleucel
    Belgium
Previous Page
1 2 3 4 … 89
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!